Incretin-based therapies and risk of pancreatic cancer in patients with type 2 diabetes: A meta-analysis of randomized controlled trials-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Incretin-based therapies and risk of pancreatic cancer in patients with type 2 diabetes: A meta-analysis of randomized controlled trials

Published:2018-01-03 Issue:4 Volume:20 Page:910-920
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obes Metab

Author:

Wang Haining¹,Liu Ye¹,Tian Qing¹,Yang Jin¹,Lu Ran¹,Zhan Siyan²^ORCID,Haukka Jari³^ORCID,Hong Tianpei¹^ORCID

Affiliation:

1. Department of Endocrinology and Metabolism; Peking University Third Hospital; Beijing China

2. Department of Epidemiology and Biostatistics, School of Public Health; Peking University Health Science Centre; Beijing China

3. Clinicum Department of Public Health; University of Helsinki; Helsinki Finland

Funder

National Natural Science Foundation of China

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/dom.13177/fullpdf

Reference71 articles.

1. Liraglutide and cardiovascular outcomes in type 2 diabetes;Marso;N Engl J Med,2016

2. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes;Marso;N Engl J Med,2016

3. Standards of Medical Care in Diabetes;American Diabetes Association;Diabetes Care,2017

4. Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies;Elashoff;Gastroenterology,2011

5. Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors;Butler;Diabetes,2013

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pancreatitis and Pancreatic Cancer Risk Among Patients With Type 2 Diabetes Receiving Dipeptidyl Peptidase 4 Inhibitors: An Updated Meta-Analysis of Randomized Controlled Trials;Clinical Therapeutics;2024-08

2. Association between nonalcholic fatty liver disease and pancreatic cancer: Epidemiology, mechanisms, and antidiabetic medication;Hepatology Research;2024-06-17

3. Efficacy and Safety of Semaglutide in Weight Loss of Non-diabetic People;Endocrine, Metabolic & Immune Disorders - Drug Targets;2024-05-28

4. Cancer biology in diabetes update: Focusing on antidiabetic drugs;Journal of Diabetes Investigation;2024-03-08

5. A Primer on Systematic Review and Meta-analysis in Diabetes Research;Diabetes Care;2023-10-27

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3